Cholesterol atheroembolism (CES) involves embolisation of cholesterol crystals from atheromatous plaques into peripheral vessels, causing multiorgan injury. Management requires a structured, evidence-informed approach covering organ support, anticoagulation decisions, and selected adjunct interventions.
Treatment is largely supportive. The framework addresses hemodynamic stability, renal support when needed, and nutritional and metabolic care. A key consideration specific to CES is the role of anticoagulation, which may need to be withdrawn or avoided.
For certain patients, an anti-inflammatory strategy has been considered alongside supportive measures.
Treatment of CES is largely supportive [10] and generally consists of fluid and blood pressure support, hemodialysis when indicated, nutritional and metabolic support.
Thus, treatment of CES generally entails withdrawal or avoidance of anticoagulation [10].
Limited evidence suggests that anti-inflammatory therapy, including corticosteroids or prostacyclin analogues, or both, may be beneficial in selected cases [11, 12].
DOI: 10.14740/jmc1804w
View source ↗